OncoMatch/Clinical Trials/NCT03701581
4-aminopyridine Treatment for Nerve Injury
Is NCT03701581 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies 4-Aminopyridine for nerve injury.
Treatment: 4-Aminopyridine — To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT1C, CT2A, CT2B, CT2C (clinical TNM)
organ-confined, non-metastatic prostate cancer (stages cT1c-T2c)
Prior therapy
Cannot have received: neo-adjuvant therapy
Neo-adjuvant therapy prior to NSRP
Cannot have received: adjuvant therapy (radiation, androgen deprivation therapy)
Planned adjuvant therapy after NSRP based on specimen pathology and stage of prostate cancer (stage T3 or greater), positive lymph nodes or positive surgical margins
Lab requirements
Kidney function
gfr >= 60 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona · Tucson, Arizona
- University of Rochester · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify